Key statistics
As of last trade Halozyme Therapeutics Inc (RV7:DUS) traded at 58.38, -14.62% below its 52-week high of 68.38, set on Feb 16, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 58.38 |
|---|---|
| High | 58.38 |
| Low | 58.38 |
| Bid | 59.62 |
| Offer | 59.94 |
| Previous close | 58.10 |
| Average volume | 7.14 |
|---|---|
| Shares outstanding | 118.02m |
| Free float | 116.09m |
| P/E (TTM) | 27.91 |
| Market cap | 8.21bn USD |
| EPS (TTM) | 2.49 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 07:11 GMT.
More ▼
Press releases
- Halozyme to Participate in Upcoming Investor Conferences
- Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
- /C O R R E C T I O N -- Nootropics Depot/
- Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update
- Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
- Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
- U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
- Jim Lang Elected to Halozyme's Board of Directors
- Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
More ▼
